NASDAQ:INSM - Insmed Stock Price, Price Target & More

Get Started

$25.88 -0.53 (-2.01 %)

(As of 05/23/2018 11:01 AM ET)

Previous Close$26.21

Today's Range$25.29 - $26.21

52-Week Range$11.49 - $33.94

Volume15,446 shs

Average Volume683,970 shs

Market Capitalization$2.02 billion

P/E Ratio-9.14

Dividend YieldN/A

Beta1.07

About Insmed (NASDAQ:INSM)

Insmed Incorporated, a biopharmaceutical company, focuses on the development and commercialization of therapies for patients with rare diseases. The company's lead product candidate is amikacin liposome inhalation suspension, which is in late-state development for adult patients with treatment refractory nontuberculous mycobacteria lung disease caused by mycobacterium avium complex. Its earlier-stage clinical pipeline also includes INS1007, an oral reversible inhibitor of dipeptidyl peptidase 1 for non-cystic fibrosis bronchiectasis and other inflammatory diseases; and INS1009, an inhaled nanoparticle formulation of a treprostinil prodrug for rare pulmonary disorders. The company was founded in 1999 and is headquartered in Bridgewater, New Jersey.

Receive INSM News and Ratings via Email

Sign-up to receive the latest news and ratings for INSM and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

SymbolNASDAQ:INSM

CUSIPN/A

Webwww.insmed.com

Phone908-977-9900

Debt

Debt-to-Equity Ratio0.70

Current Ratio20.01

Quick Ratio20.01

Price-To-Earnings

Trailing P/E Ratio-9.14

Forward P/E Ratio-6.47

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / CashN/A

Book Value$5.68 per share

Price / Book4.56

Profitability

EPS (Most Recent Fiscal Year)($2.89)

Net Income$-192,640,000.00

Net MarginsN/A

Return on Equity-68.14%

Return on Assets-46.47%

Miscellaneous

Employees214

Outstanding Shares76,620,000

Insmed (NASDAQ:INSM) Frequently Asked Questions

What is Insmed's stock symbol?

Insmed trades on the NASDAQ under the ticker symbol "INSM."

How were Insmed's earnings last quarter?

Insmed, Inc. (NASDAQ:INSM) issued its quarterly earnings data on Wednesday, May, 2nd. The biopharmaceutical company reported ($0.89) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.96) by $0.07. View Insmed's Earnings History.

What price target have analysts set for INSM?

9 equities research analysts have issued 1 year price objectives for Insmed's stock. Their forecasts range from $17.00 to $54.00. On average, they expect Insmed's share price to reach $37.4444 in the next year. View Analyst Ratings for Insmed.

Who are some of Insmed's key competitors?

Some companies that are related to Insmed include Valeant Pharmaceuticals Intl (VRX), SAGE Therapeutics (SAGE), Alkermes (ALKS), Sarepta Therapeutics (SRPT), Ionis Pharmaceuticals (IONS), Catalent (CTLT), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), Agios Pharmaceuticals (AGIO), Dr. Reddy's Laboratories (RDY), United Therapeutics (UTHR), Taro Pharmaceutical Industries (TARO), Hutchison China MediTech (HCM), FibroGen (FGEN) and GW Pharmaceuticals (GWPH).

Who are Insmed's key executives?

Insmed's management team includes the folowing people:

Mr. William H. Lewis, Pres, CEO & Director (Age 49)
Ms. Christine A. Pellizzari, Chief Legal Officer (Age 50)
Ms. S. Nicole Schaeffer, Chief People Strategy Officer (Age 50)
Dr. Eugene J. Sullivan M.D., FCCP, Chief Product Strategy Officer (Age 53)
Mr. Andrew T. Drechsler, Advisor (Age 46)

Has Insmed been receiving favorable news coverage?

Media coverage about INSM stock has trended somewhat positive recently, according to Accern Sentiment. The research group ranks the sentiment of news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Insmed earned a media sentiment score of 0.19 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 46.61 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

Who are Insmed's major shareholders?

Insmed's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Palo Alto Investors LP (9.34%), Redmile Group LLC (2.83%), Foresite Capital Management II LLC (1.26%), Northern Trust Corp (1.25%), Nexthera Capital LP (1.20%) and Lord Abbett & CO. LLC (1.04%). Company insiders that own Insmed stock include Andrew T Drechsler, Christine A Pellizzari, Donald J Hayden Jr, Melvin Md Sharoky, Myrtle S Potter and Orlov S Nicole Schaeffer. View Institutional Ownership Trends for Insmed.

Which major investors are selling Insmed stock?

INSM stock was sold by a variety of institutional investors in the last quarter, including Redmile Group LLC, C WorldWide Group Holding A S, Victory Capital Management Inc., Teacher Retirement System of Texas, Sei Investments Co., Legal & General Group Plc, California State Teachers Retirement System and American International Group Inc.. Company insiders that have sold Insmed company stock in the last year include Donald J Hayden Jr and Melvin Md Sharoky. View Insider Buying and Selling for Insmed.

Which major investors are buying Insmed stock?

INSM stock was purchased by a variety of institutional investors in the last quarter, including Palo Alto Investors LP, Foresite Capital Management II LLC, Nexthera Capital LP, Bellevue Group AG, Summit Trail Advisors LLC, PointState Capital LP, Lord Abbett & CO. LLC and California Public Employees Retirement System. View Insider Buying and Selling for Insmed.

How do I buy shares of Insmed?

Shares of INSM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Insmed's stock price today?

One share of INSM stock can currently be purchased for approximately $25.52.

How big of a company is Insmed?

Insmed has a market capitalization of $2.02 billion. The biopharmaceutical company earns $-192,640,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Insmed employs 214 workers across the globe.

How can I contact Insmed?

Insmed's mailing address is 10 Finderne Avenue Building 10, Bridgewater NJ, 08807. The biopharmaceutical company can be reached via phone at 908-977-9900 or via email at [email protected]

MarketBeat Community Rating for Insmed (INSM)

Community Ranking:		2.6 out of 5 ( )
Outperform Votes:		301 (Vote Outperform)
Underperform Votes:		285 (Vote Underperform)
Total Votes:		586

MarketBeat's community ratings are surveys of what our community members think about Insmed and other stocks. Vote "Outperform" if you believe INSM will outperform the S&P 500 over the long term. Vote "Underperform" if you believe INSM will underperform the S&P 500 over the long term. You may vote once every thirty days.

Insmed (NASDAQ:INSM) Price Target and Consensus Rating

(How are Consensus Ratings Calculated?)

9 Wall Street analysts have issued ratings and price targets for Insmed in the last 12 months. Their average twelve-month price target is $37.4444, suggesting that the stock has a possible upside of 44.68%. The high price target for INSM is $54.00 and the low price target for INSM is $17.00. There are currently 1 hold rating and 8 buy ratings for the stock, resulting in a consensus rating of "Buy."

	Today	30 Days Ago	90 Days Ago	180 Days Ago
Consensus Rating:	Buy	Buy	Buy	Buy
Consensus Rating Score:	2.89	2.89	2.75	2.86
Ratings Breakdown:	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 8 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 2 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)	0 Sell Rating(s) 1 Hold Rating(s) 6 Buy Rating(s) 0 Strong Buy Rating(s)
Consensus Price Target:	$37.4444	$37.4444	$37.25	$36.7143
Price Target Upside:	44.68% upside	59.20% upside	25.97% upside	22.34% upside

Insmed (NASDAQ:INSM) Consensus Price Target History

Price Target History for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Analyst Ratings History

Show:

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
4/23/2018	Credit Suisse Group	Upgrade	Neutral ➝ Outperform	$27.00 ➝ $31.00	High
3/21/2018	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight	$39.00	Medium
1/4/2018	HC Wainwright	Reiterated Rating	Buy	$35.00	Medium
1/4/2018	Robert W. Baird	Reiterated Rating	Outperform ➝ Positive	$32.00 ➝ $42.00	High
11/3/2017	Cowen	Reiterated Rating	Buy	$54.00	N/A
9/6/2017	Stifel Nicolaus	Reiterated Rating	Buy	$27.00 ➝ $43.00	High
9/5/2017	Leerink Swann	Boost Price Target	Outperform	$27.00 ➝ $36.00	High
9/5/2017	Evercore ISI	Boost Price Target	Outperform ➝ Outperform	$28.00 ➝ $40.00	High
6/11/2017	Citigroup	Reiterated Rating	Neutral	$14.00 ➝ $17.00	High
8/21/2016	Piper Jaffray Companies	Set Price Target	Buy	$24.00	N/A

(Data available from 5/23/2016 forward)

Insmed (NASDAQ:INSM) Earnings History and Estimates Chart

Earnings by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ:INSM) Earnings Estimates

2018 EPS Consensus Estimate: ($3.76)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2018	1	($0.92)	($0.92)	($0.92)
Q2 2018	1	($0.92)	($0.92)	($0.92)
Q3 2018	1	($1.02)	($1.02)	($1.02)
Q4 2018	1	($0.90)	($0.90)	($0.90)

Insmed (NASDAQ INSM) Earnings History by Quarter

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call
5/2/2018	Q1 2018	($0.96)	($0.89)			View	N/A
2/23/2018	Q4 2017	($0.67)	($0.85)			View	Listen
11/2/2017	Q3 2017	($0.69)	($0.69)			View	N/A
8/3/2017	Q2 2017	($0.63)	($0.72)			View	Listen
5/3/2017	Q1 2017	($0.60)	($0.60)	$0.30 million		View	Listen
2/23/2017	Q316	($0.89)	($1.1040)	$0.30 million		View	N/A
11/3/2016	Q216	($0.59)	($0.61)	$0.10 million		View	N/A
8/4/2016	Q2	($0.56)	($0.59)			View	N/A
5/5/2016	Q1	($0.56)	($0.54)			View	N/A
2/25/2016	Q415	($0.49)	($0.51)			View	N/A
11/6/2015	Q315	($0.48)	($0.50)			View	N/A
8/6/2015	Q2	($0.48)	($0.47)			View	N/A
5/7/2015	Q115	($0.49)	($0.55)			View	N/A
2/27/2015	Q414	($0.57)	($0.36)			View	N/A
11/6/2014	Q314	($0.51)	($0.54)			View	N/A
8/6/2014	Q214	($0.50)	($0.59)			View	N/A
5/8/2014	Q114	($0.39)	($0.36)			View	N/A
3/6/2014	Q413	($0.45)	($0.41)			View	N/A
11/5/2013	Q313	($0.41)	($0.46)			View	Listen
8/6/2013	Q2 2013	($0.32)	($0.28)	$5.38 million	$11.50 million	View	Listen
5/7/2013	Q1 2013	($0.46)	($0.43)			View	Listen
3/18/2013	Q4 2012	($0.31)	($0.49)			View	N/A
11/7/2012	Q312	($0.42)	($0.38)			View	N/A
8/7/2012	Q2 2012	($0.31)	($0.39)			View	N/A
5/8/2012	Q1 2012	($0.34)	($0.28)			View	N/A
3/13/2012	Q4 2011	($0.38)	($0.28)			View	N/A
11/8/2011	Q3 2011	($0.28)	($0.35)			View	N/A
8/8/2011	Q2 2011	($0.33)	($0.40)			View	N/A
5/10/2011	Q1 2011	($0.32)	($0.37)			View	N/A
3/10/2011	Q4 2010	($0.10)	($0.48)			View	N/A
11/3/2010	Q3 2010		($0.03)			View	N/A
8/4/2010	Q2 2010		($0.03)			View	N/A
5/6/2010	Q1 2010		$0.01			View	N/A
3/15/2010	Q4 2009		$0.10			View	N/A
11/6/2009	Q3 2009		($0.01)			View	N/A
8/13/2009	Q2 2009		($0.13)			View	N/A
5/13/2009	Q1 2009		$2.83			View	N/A
3/11/2009	Q4 2008		($0.32)			View	N/A
10/30/2008	Q3 2008		($0.18)			View	N/A
8/8/2008	Q2 2008		($0.38)			View	N/A
5/8/2008	Q1 2008		($0.40)			View	N/A
3/4/2008	Q4 2007	($0.30)	($0.27)			View	N/A

(Earnings results data provided by Zacks Investment Research)

Insmed (NASDAQ:INSM) Dividend History by Quarter

Announced	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date

(Data available from 1/1/2013 forward)

Insmed (NASDAQ INSM) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 3.88%

Insider Trading History for Insmed (NASDAQ:INSM)

Institutional Ownership by Quarter for Insmed (NASDAQ:INSM)

Insmed (NASDAQ INSM) Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
11/14/2017	Donald J Hayden Jr	Director	Sell	15,000	$32.50	$487,500.00	71,131
9/7/2017	Donald J Hayden Jr	Director	Sell	45,000	$29.67	$1,335,150.00	71,131
9/6/2017	Melvin Md Sharoky	Director	Sell	50,000	$27.37	$1,368,500.00
5/31/2017	Christine A Pellizzari	General Counsel	Buy	10,000	$15.14	$151,400.00	27,300
12/15/2016	Christine A Pellizzari	General Counsel	Buy	20,000	$12.81	$256,200.00	10,000
12/14/2016	Myrtle S Potter	Director	Sell	6,466	$12.79	$82,700.14	5,000
11/14/2016	Andrew T Drechsler	CFO	Sell	45,000	$14.67	$660,150.00	20,000
11/9/2016	Orlov S Nicole Schaeffer	SVP	Sell	68,774	$11.95	$821,849.30	37,500
2/1/2016	William Lewis	CEO	Buy	50,000	$13.34	$667,000.00	96,972
9/2/2015	Donald J. Hayden, Jr.	Director	Sell	25,000	$24.06	$601,500.00	36,687
5/12/2015	Mark Quigley	VP	Sell	18,750	$22.07	$413,812.50
8/13/2014	Melvin Md Sharoky	Director	Buy	88,889	$11.25	$1,000,001.25
11/1/2013	William Lewis	CEO	Buy	5,233	$14.28	$74,727.24
7/22/2013	Fmr Llc	Insider	Sell	158,758	$12.02	$1,908,271.16
7/18/2013	Fmr Llc	Insider	Sell	310,227	$11.49	$3,564,508.23
7/15/2013	Fmr Llc	Insider	Sell	161,531	$10.79	$1,742,919.49
7/9/2013	Fmr Llc	Insider	Sell	146,599	$10.01	$1,467,455.99
7/3/2013	Fmr Llc	Insider	Sell	365,779	$9.96	$3,643,158.84
7/1/2013	William Lewis	CEO	Buy	7,585	$9.83	$74,560.55
6/24/2013	Fmr Llc	Insider	Sell	50,000	$12.00	$600,000.00
6/20/2013	Fmr Llc	Insider	Sell	143,088	$12.24	$1,751,397.12
6/12/2013	Fmr Llc	Insider	Sell	85,758	$13.00	$1,114,854.00
6/6/2013	Fmr Llc	Insider	Sell	130,557	$12.85	$1,677,657.45
4/1/2013	William Lewis	CEO	Buy	9,816	$7.58	$74,405.28
1/9/2013	William Lewis	CEO	Buy	10,770	$6.90	$74,313.00
12/3/2012	William Lewis	CEO	Buy	13,568	$7.36	$99,860.48

(Data available from 1/1/2013 forward)

Insmed (NASDAQ INSM) News Headlines

Source:

Date	Headline
	Benzinga's Daily Biotech Pulse: Insmed Presents Data, Pfenex Pulls Back On Offering, Oncolytics Listing www.benzinga.com - May 23 at 9:12 AM
	Insmed Announces Presentations at the American Thoracic Society 2018 International Conference finance.yahoo.com - May 23 at 9:12 AM
	3 Things In Biotech, May 17: Insmed's Approval Chance, Pfizer Finally Proves Similar, Eagle Ascends seekingalpha.com - May 18 at 10:22 AM
	Insmed (INSM) Names Leo Lee to Board www.streetinsider.com - May 18 at 10:22 AM
	Blog Exposure - FDA Accepted for Review Insmed’s Marketing Application for ALIS in NTM Lung Disease Caused by MAC finance.yahoo.com - May 18 at 10:22 AM
	Insmed Appoints Leo Lee to its Board of Directors finance.yahoo.com - May 17 at 4:48 PM
	BRIEF-Insmed Announces FDA Acceptance For Filing Of NDA For Lung Disease Treatment www.reuters.com - May 16 at 9:44 AM
	Insmed (INSM) Announces FDA Acceptance for Filing of NDA for ALIS in NTM Lung Disease Caused by MAC www.streetinsider.com - May 16 at 9:44 AM
	Insmed Announces FDA Acceptance for Filing of New Drug Application for ALIS in NTM Lung Disease Caused by MAC finance.yahoo.com - May 16 at 9:44 AM
	Insmed (INSM) Stock Rating Upgraded by ValuEngine www.americanbankingnews.com - May 10 at 8:37 PM
	-$0.98 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter www.americanbankingnews.com - May 7 at 3:30 AM
	Insmed, Inc. (INSM) Expected to Post Q2 2018 Earnings of ($0.92) Per Share www.americanbankingnews.com - May 7 at 2:07 AM
	Insmed's (INSM) CEO William Lewis on Q1 2018 Results - Earnings Call Transcript seekingalpha.com - May 5 at 9:47 AM
	Insmed (INSM) Issues Quarterly Earnings Results, Beats Expectations By $0.07 EPS www.americanbankingnews.com - May 3 at 5:38 PM
	Today's Research Reports on Trending Tickers: Insmed and Arena Pharmaceuticals finance.yahoo.com - May 3 at 9:21 AM
	Edited Transcript of INSM earnings conference call or presentation 2-May-18 12:30pm GMT finance.yahoo.com - May 3 at 9:21 AM
	Insmed, Inc. (INSM) Given Average Rating of "Buy" by Analysts www.americanbankingnews.com - May 3 at 1:35 AM
	Insmed (INSM) PT Raised to $56 at Cowen www.streetinsider.com - May 2 at 4:30 PM
	Form 10-Q INSMED Inc For: Mar 31 www.streetinsider.com - May 2 at 4:30 PM
	BRIEF-Insmed Reports Q1 Loss Per Share $0.89 www.reuters.com - May 2 at 9:25 AM
	Insmed Reports First Quarter 2018 Financial Results and Provides Business Update finance.yahoo.com - May 2 at 9:25 AM
	Insmed: 1Q Earnings Snapshot finance.yahoo.com - May 2 at 9:25 AM
	Insmed (INSM) Rating Increased to Hold at Zacks Investment Research www.americanbankingnews.com - May 1 at 7:52 AM
	Insmed to Host First Quarter 2018 Financial Results Conference Call on Wednesday, May 2, 2018 finance.yahoo.com - April 25 at 9:35 AM
	Insmed (INSM) Set to Announce Quarterly Earnings on Tuesday www.americanbankingnews.com - April 24 at 7:28 AM
	Insmed Inc. (INSM) Has Climbed To A 1-Month High www.nasdaq.com - April 23 at 4:25 PM
	Insmed Shares To Outperform Through 2018 After 'Slow Start,' Credit Suisse Says In Upgrade finance.yahoo.com - April 23 at 4:25 PM
	Insmed (INSM) Raised to Outperform at Credit Suisse Group www.americanbankingnews.com - April 23 at 8:46 AM
	Zacks: Brokerages Anticipate Insmed, Inc. (INSM) Will Post Earnings of -$0.80 Per Share www.americanbankingnews.com - April 20 at 1:26 AM
	Insmed (INSM) Upgraded by Zacks Investment Research to Buy www.americanbankingnews.com - April 19 at 9:40 PM
	Insmed's (INSM) Buy Rating Reaffirmed at HC Wainwright www.americanbankingnews.com - April 14 at 10:35 AM
	ValuEngine Lowers Insmed (INSM) to Sell www.americanbankingnews.com - April 13 at 1:37 PM
	Insmed (INSM) Rating Increased to Hold at BidaskClub www.americanbankingnews.com - April 11 at 11:01 AM
	BidaskClub Downgrades Insmed (INSM) to Strong Sell www.americanbankingnews.com - April 10 at 3:54 PM
	Insmed (INSM): Moving Average Crossover Alert finance.yahoo.com - April 10 at 9:54 AM
	Insmed (INSM) Lifted to "Buy" at ValuEngine www.americanbankingnews.com - April 10 at 12:37 AM
	Insmed (INSM) Rating Increased to Hold at ValuEngine www.americanbankingnews.com - April 9 at 11:35 AM
	Insmed, Inc. (INSM) Receives Average Recommendation of "Hold" from Analysts www.americanbankingnews.com - April 8 at 1:30 AM
	-$0.81 Earnings Per Share Expected for Insmed, Inc. (INSM) This Quarter www.americanbankingnews.com - April 3 at 1:14 AM
	Insmed (INSM) Rating Reiterated by HC Wainwright www.americanbankingnews.com - April 1 at 7:35 PM
	Insmed (INSM) Downgraded by Zacks Investment Research www.americanbankingnews.com - April 1 at 7:00 PM
	Insmed (INSM) Lowered to "Sell" at Zacks Investment Research www.americanbankingnews.com - March 30 at 8:24 PM
	Insmed (INSM) Lifted to "Buy" at Zacks Investment Research www.americanbankingnews.com - March 30 at 1:28 PM
	Insmed (INSM) Submits NDA to FDA for ALIS in NTM Lung Disease Caused by MAC www.streetinsider.com - March 29 at 9:53 AM
	Insmed Submits New Drug Application to FDA for ALIS in NTM Lung Disease Caused by MAC finance.yahoo.com - March 29 at 9:53 AM
	Insmed (INSM) Lifted to Buy at Zacks Investment Research www.americanbankingnews.com - March 27 at 9:44 PM
	Zacks Investment Research Lowers Insmed (INSM) to Hold www.americanbankingnews.com - March 27 at 1:16 PM
	Insmed (INSM) Upgraded to Hold at BidaskClub www.americanbankingnews.com - March 25 at 2:34 PM
	Insmed (INSM) Downgraded to "Sell" at BidaskClub www.americanbankingnews.com - March 24 at 10:48 AM
	Commit To Buy Insmed At $15, Earn 15.8% Annualized Using Options - Nasdaq www.nasdaq.com - March 23 at 4:22 PM

Insmed (NASDAQ:INSM) SEC Filings

Form Type:

Ownership Filings:

This page is loading this company's SEC Filings. Please wait...

Insmed (NASDAQ:INSM) Income Statement, Balance Sheet and Cash Flow Statement

Insmed (NASDAQ INSM) Stock Chart for Wednesday, May, 23, 2018

Loading chart…

This page was last updated on 5/23/2018 by MarketBeat.com Staff